news
First AI-generated small molecule drug enters Phase II trial
Insilico Medicine’s novel AI-generated small molecule inhibitor drug represents a new milestone in pharmaceutical drug development.
List view / Grid view
Idiopathic pulmonary fibrosis (IPF)
news
EMA human medicines committee (CHMP) highlights, November 2022
The Committee for Medicinal Products for Human Use (CHMP)’s November meeting consisted of approval recommendations for four medicines, including a biosimilar for osteoporosis and a new COVID-19 vaccine.
news
Trial data reveals potential new treatment for pulmonary fibrosis patients
The data from the 12 week trial showed phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
news
EMA’s human medicines committee (CHMP) April 2022 meeting highlights
At its latest meeting, EMA’s human medicines committee (CHMP) recommended the approval of four medicines, seven extensions of therapeutic indication and laid out recommendations for diabetes treatment outside of the EU.
news
Biotech company Promedior merges with Roche
Roche has successfully completed its purchase of Promedior, Inc. along with its entire portfolio of fibrotic disease therapeutics.
news
Cypralis granted new Innovate UK feasibility stage award for chronic pancreatitis
Cypralis, has been awarded funding by Innovate UK to develop cyclophilin inhibitors targeting fibrotic diseases...
news
First patient enrolled in IPF biomarker study of Ofev
30 June 2016 | By Victoria White, Digital Content Producer
INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
news
Merck enters the IPF market through Afferent acquisition
27 June 2016 | By Victoria White, Digital Content Producer
Merck’s acquisition of Afferent Pharmaceuticals will provide it with an entry-platform into the fast-growing IPF market, according to GlobalData...
news
IPF market will grow to $3.2 billion by 2025, says GlobalData
21 June 2016 | By Victoria White, Digital Content Producer
The idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over $900 million in 2015 to $3.2 billion by 2025, according to GlobalData...
